Highlights | Ophthalmology | JAMA Ophthalmology | JAMA Network
[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 1,041
Citations 0
In This Issue of JAMA Ophthalmology
October 2013


JAMA Ophthalmol. 2013;131(10):1259. doi:10.1001/jamaophthalmol.2013.4136

Tanihara and colleagues studied the short-term results of topically administered selective Rho kinase inhibitor, K-115, in a randomized, double-masked, placebo-controlled clinical trial. Fifty healthy volunteers received a single instillation, while another 50 healthy volunteers received repeated instillation of increasing concentrations in a stepwise manner. Maximal intraocular pressure reductions were noted 1 to 2 hours after instillation, with slight to mild conjunctival hyperemia found in more than half of the participants after each instillation of the drug, typically resolving within 90 minutes. These findings suggest a potential benefit of this class of medications, pending further clinical trials.

Continuing Medical Education